|
(Health-NewsWire.Net, March 26, 2020 ) Market Overview
The Global Positron-Emission Tomography (PET) Market is expected to grow at a CAGR of 5.6% during the forecasting period (2019-2026).
Positron-Emission Tomography (PET) Market is a nuclear medicine functional imaging technique that is used to observe the metabolic process in the body as an aid to diagnosis of disease. PET offers significant advantages, including excellent contrast and resolution and reduced ionizing radiation, as compared to well-established PET.
Download free sample: https://www.datamintelligence.com/download-sample/positron-emission-tomography-market
Market Dynamics
The Positron-Emission Tomography (PET) market is growing due to several factors such as, rising demand for PET analysis in radio pharmaceuticals, technological advancements in pet imaging, and rising incidence of various chronic diseases
Technical trends in the PET imaging such as the introduction of integrated imaging system leading to medical revolution is one of the primary drivers leading to the growth of the PET market globally. For instance, in April 2019, according to the Journal of Nuclear Medicine, researchers have discovered a way to better predict progression of Alzheimer's disease. Amyloid PET imaging is a diagnostic technique that determines whether patients with memory complaints have amyloid plaques in the brain, an indicator of Alzheimer's disease.
In 2018, the EXPLORER human scanner (a total-body PET/CT scanner) was introduced which has proven its ability to produce quality images in less time, coupled with a much lower dose of radiotracer (18F-FDG).
The key players are developing new technologically advanced PET imaging systems. For instance, in June 2019, United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced the first U.S. clinical installation of the uMI 550 DIGITAL PET/CT system. The second United Imaging PET/CT system installed in the U.S., the uMI 550 is now in use at Southwest X-Ray, LP in El Paso, Texas. United Imaging is continuing to rapidly build its momentum in the U.S. by sharing its technological advancements in PET/CT and PET/MR with leading professionals in molecular imaging and nuclear medicine.
Market Segmentation
Based on product type, the global Positron-Emission Tomography (PET) market is segmented into Full-Ring PET Scanners and Partial Ring PET Scanners. Among these, the full ring PET scanners segment is estimated to hold significant market share during the forecast period (2019-2026) segment, as a full ring PET scanner has no gaps and is impractical for use when the patient is scanned while lying on the proton therapy bed compared to the partial PET scanner and the improved timing resolution (such as 300ps) leads to reduced error even in a full ring scanner.
By application, the oncology segment accounted for the largest market share in 2018, as Positron Emission Tomography (PET CT) is an effective nuclear imaging techniques used to confirm the presence of the various cancers. In the field of oncology, the PET (positron emission tomography) uses FDG (18Fluorine-2-fluoro-2-Deoxy-d-glucose) as the radiopharmaceutical, as it demonstrates the increased metabolism by malignant cells, when compared to that of normal cells. With rising incidence of cancer globally, the demand for advanced imaging techniques is growing resulting in the growth of the market. Oncology accounts for more than 80% of the PET and PET/CT procedures performed, whereas cardiology and neurology account for about 5% each. According to the National Oncology PET Registry, about 84% of the slightly more than 1,600 PET facilities in the United States have PET/CT systems. The rising number of cases of cancer is creating tremendous opportunities for market players of nuclear imaging. According to American Cancer society (2019), the estimated numbers of new cancer cases diagnosed is about 1,762,450 in 2019 while in 2018, there were 1,735,350 new cancer cases diagnosed in the United States. Thus, the need for early diagnosis and treatment of cancer cases has enhanced the usage of PET scanners, and has led to the growth of the market.
Geographical Analysis
North America holds the dominant market share for Positron-Emission Tomography (PET) in 2018, and is expected to maintain the growth over the forecast period, increasing prevalence of cancer in United States, rising number PET scans, and introduction of new devices for the imaging by manuafcturers.
The volume of PET procedures in the United States is approximately two million per year. There are about 2,670 PET scanners in hospitals across the U.S. that collectively performs about 2 million scans per year. In February 2018, the FDA and the Nuclear Regulatory Commission (NRC) of the United States has approved the compact RadioGenix System from NorthStar, a Beloit, Wisconsin firm, to produce technetium-99m from non-uranium sourced molybdenum-99 (Mo-99). It is the first time in 30 years that America has its own source of Tc-99m, as it was previously available only from Canada, Poland, South Africa, and a few other places. Delivering the radioactive material from afar is a logistical nightmare that drives up the cost of the radioisotope by the time it reaches a U.S. imaging center.
Competitive Landscape
Some of the major manufacturers in the Positron-Emission Tomography (PET) market are: GE Healthcare, Philips Healthcare, Siemens Healthcare, Positron Corporation, Segami Corporation, Spectrum Dynamics Ltd., Naviscan Inc, MedX Holdings Inc., United Imaging, Neusoft Medical Systems, among others.
The key players are adopting various growth strategies such as new product launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the Positron-Emission Tomography (PET) market globally. For instance,
In February 2019, Siemens Healthineers introduced a new Biograph Vision positron emission tomography/computed tomography (PET/CT) system which has been installed at the Hospital of the University of Pennsylvania (HUP) in Philadelphia, the first health care institution in the United States to install the technology.
In December 2018, Subtle Medical, a firm in California, won both FDA clearance and the European CE Mark of approval to introduce its SubltePET system on both sides of the Atlantic. The system uses artificial intelligence techniques to improve the quality of fast positron-emission tomography (PET) scans, allowing patients to go through exams faster than before without suffering from poorer image resolution.
In June 2017, Siemens won FDA clearance for its Biograph Horizon Flow edition, a budget friendly positron emission tomography/computed tomography (PET/CT) scanner that includes some advanced features of its more expensive cousin. The main selling point is that the new device includes FlowMotion continuous bed motion scanning technology, an offering that was previously introduced on Siemens Biograph mCT Flow PET/CT.
View full report: https://www.datamintelligence.com/research-report/positron-emission-tomography-market
Enquiry before buying: https://www.datamintelligence.com/enquiry/positron-emission-tomography-market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
DataM Intelligence
Sai Kiran
+1 877 441 4866
pr@datamintelligence.com
Source: EmailWire.Com 
|
